521 related articles for article (PubMed ID: 9147420)
1. TAR and Sp1-independent transactivation of HIV long terminal repeat by the Tat protein in the presence of human cytomegalovirus IE1/IE2.
Dal Monte P; Landini MP; Sinclair J; Virelizier JL; Michelson S
AIDS; 1997 Mar; 11(3):297-303. PubMed ID: 9147420
[TBL] [Abstract][Full Text] [Related]
2. Human cytomegalovirus product UL44 downregulates the transactivation of HIV-1 long terminal repeat.
Boccuni MC; Campanini F; Battista MC; Bergamini G; Dal Monte P; Ripalti A; Landini MP
AIDS; 1998 Mar; 12(4):365-72. PubMed ID: 9520165
[TBL] [Abstract][Full Text] [Related]
3. A 10-base-pair element of the human immunodeficiency virus type 1 long terminal repeat (LTR) is an absolute requirement for transactivation by the human cytomegalovirus 72-kilodalton IE1 protein but can be compensated for by other LTR regions in transactivation by the 80-kilodalton IE2 protein.
Walker S; Hagemeier C; Sissons JG; Sinclair JH
J Virol; 1992 Mar; 66(3):1543-50. PubMed ID: 1310765
[TBL] [Abstract][Full Text] [Related]
4. Identification of human cytomegalovirus target sequences in the human immunodeficiency virus long terminal repeat. Potential role of IE2-86 binding to sequences between -120 and -20 in promoter transactivation.
Yurochko AD; Huong SM; Huang ES
J Hum Virol; 1999; 2(2):81-90. PubMed ID: 10225210
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the human cytomegalovirus immediate-early 2 protein defines regions and amino acid motifs important in transactivation of transcription from the HIV-1 LTR promoter.
Yeung KC; Stoltzfus CM; Stinski MF
Virology; 1993 Aug; 195(2):786-92. PubMed ID: 8337845
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
[TBL] [Abstract][Full Text] [Related]
7. Transactivation activity of the human cytomegalovirus IE2 protein occurs at steps subsequent to TATA box-binding protein recruitment.
Kim JM; Hong Y; Jeang KT; Kim S
J Gen Virol; 2000 Jan; 81(Pt 1):37-46. PubMed ID: 10640540
[TBL] [Abstract][Full Text] [Related]
8. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat.
Yang L; Morris GF; Lockyer JM; Lu M; Wang Z; Morris CB
Virology; 1997 Aug; 235(1):48-64. PubMed ID: 9300036
[TBL] [Abstract][Full Text] [Related]
9. Disruption of PML-associated nuclear bodies by IE1 correlates with efficient early stages of viral gene expression and DNA replication in human cytomegalovirus infection.
Ahn JH; Hayward GS
Virology; 2000 Aug; 274(1):39-55. PubMed ID: 10936087
[TBL] [Abstract][Full Text] [Related]
10. Essential role of NF-kappa B in transactivation of the human immunodeficiency virus long terminal repeat by the human cytomegalovirus 1E1 protein.
Kim S; Yu SS; Kim VN
J Gen Virol; 1996 Jan; 77 ( Pt 1)():83-91. PubMed ID: 8558131
[TBL] [Abstract][Full Text] [Related]
11. Transactivation of a human cytomegalovirus early promoter by gene products from the immediate-early gene IE2 and augmentation by IE1: mutational analysis of the viral proteins.
Malone CL; Vesole DH; Stinski MF
J Virol; 1990 Apr; 64(4):1498-506. PubMed ID: 2157038
[TBL] [Abstract][Full Text] [Related]
12. Artificial recruitment of Sp1 or TBP can replace the role of IE1 in the synergistic transactivation by IE1 and IE2.
Kim JM; Hong Y; Kim S
Biochem Biophys Res Commun; 2000 Mar; 269(2):302-8. PubMed ID: 10708547
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Tat protein can transactivate a heterologous TATAA element independent of viral promoter sequences and the trans-activation response element.
Roebuck KA; Rabbi MF; Kagnoff MF
AIDS; 1997 Feb; 11(2):139-46. PubMed ID: 9030359
[TBL] [Abstract][Full Text] [Related]
14. Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site.
Schafer SL; Vlach J; Pitha PM
J Virol; 1996 Oct; 70(10):6937-46. PubMed ID: 8794337
[TBL] [Abstract][Full Text] [Related]
15. Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.
Beauparlant P; Kwon H; Clarke M; Lin R; Sonenberg N; Wainberg M; Hiscott J
J Virol; 1996 Sep; 70(9):5777-85. PubMed ID: 8709193
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 regulatory protein tat induces RNA binding proteins in central nervous system cells that associate with the viral trans-acting-response regulatory motif.
Kundu M; Ansari SA; Chepenik LG; Pomerantz RJ; Khalili K; Rappaport J; Amini S
J Hum Virol; 1999; 2(2):72-80. PubMed ID: 10225209
[TBL] [Abstract][Full Text] [Related]
17. Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein.
Hwang ES; Zhang Z; Cai H; Huang DY; Huong SM; Cha CY; Huang ES
J Virol; 2009 Dec; 83(23):12388-98. PubMed ID: 19776115
[TBL] [Abstract][Full Text] [Related]
18. The 72K IE1 and 80K IE2 proteins of human cytomegalovirus independently trans-activate the c-fos, c-myc and hsp70 promoters via basal promoter elements.
Hagemeier C; Walker SM; Sissons PJ; Sinclair JH
J Gen Virol; 1992 Sep; 73 ( Pt 9)():2385-93. PubMed ID: 1328493
[TBL] [Abstract][Full Text] [Related]
19. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells.
Ahn JH; Hayward GS
J Virol; 1997 Jun; 71(6):4599-613. PubMed ID: 9151854
[TBL] [Abstract][Full Text] [Related]
20. The human cytomegalovirus 80-kilodalton but not the 72-kilodalton immediate-early protein transactivates heterologous promoters in a TATA box-dependent mechanism and interacts directly with TFIID.
Hagemeier C; Walker S; Caswell R; Kouzarides T; Sinclair J
J Virol; 1992 Jul; 66(7):4452-6. PubMed ID: 1318414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
